Ulrich Lücking

Ulrich Lücking is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG, his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his path Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.

Prior to joining the industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.